Expert group on regulatory issues of Indian vaccine industry

Image
Press Trust of India New Delhi
Last Updated : Nov 10 2016 | 1:57 PM IST
The Union Health Ministry today said it will form an expert group to examine regulatory issues for Indian vaccine industry.
It also urged the domestic vaccines manufacturers to accord prime importance to meeting domestic demand and also to take initiatives in developing critical vaccines.
"Indian vaccines manufacturers should accord prime importance to meeting domestic demand, upscale research and development related work, and also take initiatives in developing critical vaccines such as Pneumococcal conjugate vaccine (PCV)and Human Papillomavirus (HPV) vaccines," the Union Health Secretary, C K Mishra, said.
He was addressing the inaugural session of the CII National Conference on Vaccine Industry in India 'Reforms required for early accessibility, growth and sustained competitiveness' today.
Dr GN Singh, Drug Controller General of India, Central Drugs Standard Control Organization, said that the government will form an expert group to examine regulatory issues for Indian vaccine industry.
This expert group would work towards speedy resolution of issues in time-bound manner without compromising critical aspects like quality, patient safety and patient management, he said.
Mishra also lauded the efforts of Indian vaccines players in leaving a mark on global landscape as leading supplier of vaccines to world, and said that it is encouraging to witness that there has never been an instance of shortage of vaccines in India.
He asserted that the entire Indian Healthcare industry has to get involved for an effective healthcare delivery in Indi; and "we must move from health for all to health by all, whereby the vaccine industry has a critical transformational role to play."
The Health Secretary said that the Government is committed to putting together resources for Mission Indradhanush.
Mission Indradhanush is a government initiative to ensure full immunisation of all children in India.
Besides, he stressed that both industry and government should continue nurturing the symbiotic relationship thereby taking vaccine industry to a higher level.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 10 2016 | 1:57 PM IST

Next Story